151 related articles for article (PubMed ID: 24900235)
1. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.
Xue CB; Chen L; Cao G; Zhang K; Wang A; Meloni D; Glenn J; Anand R; Xia M; Kong L; Huang T; Feng H; Zheng C; Li M; Galya L; Zhou J; Shin N; Baribaud F; Solomon K; Scherle P; Zhao B; Diamond S; Emm T; Keller D; Contel N; Yeleswaram S; Vaddi K; Hollis G; Newton R; Friedman S; Metcalf B
ACS Med Chem Lett; 2010 Dec; 1(9):483-7. PubMed ID: 24900235
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
Palani A; Shapiro S; Josien H; Bara T; Clader JW; Greenlee WJ; Cox K; Strizki JM; Baroudy BM
J Med Chem; 2002 Jul; 45(14):3143-60. PubMed ID: 12086500
[TBL] [Abstract][Full Text] [Related]
5. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.
Tagat JR; Steensma RW; McCombie SW; Nazareno DV; Lin SI; Neustadt BR; Cox K; Xu S; Wojcik L; Murray MG; Vantuno N; Baroudy BM; Strizki JM
J Med Chem; 2001 Oct; 44(21):3343-6. PubMed ID: 11585438
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
Palani A; Shapiro S; Clader JW; Greenlee WJ; Cox K; Strizki J; Endres M; Baroudy BM
J Med Chem; 2001 Oct; 44(21):3339-42. PubMed ID: 11585437
[TBL] [Abstract][Full Text] [Related]
7. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
[TBL] [Abstract][Full Text] [Related]
8. Recent advances of CCR5 antagonists.
Baba M
Curr Opin HIV AIDS; 2006 Sep; 1(5):367-72. PubMed ID: 19372835
[TBL] [Abstract][Full Text] [Related]
9. Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Seto M; Aikawa K; Miyamoto N; Aramaki Y; Kanzaki N; Takashima K; Kuze Y; Iizawa Y; Baba M; Shiraishi M
J Med Chem; 2006 Mar; 49(6):2037-48. PubMed ID: 16539392
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
[TBL] [Abstract][Full Text] [Related]
11. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
12. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
[TBL] [Abstract][Full Text] [Related]
13. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
14. Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.
Yang MG; Xiao Z; Zhao R; Tebben AJ; Wang B; Cherney RJ; Batt DG; Brown GD; Cvijic ME; Duncia JV; Gallela MA; Gardner DS; Khandelwal P; Malley MF; Pang J; Rose AV; Santella JB; Sarjeant AA; Xu S; Mathur A; Mandlekar S; Vuppugalla R; Zhao Q; Carter PH
ACS Med Chem Lett; 2021 Jun; 12(6):969-975. PubMed ID: 34141082
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.
Strizki JM; Tremblay C; Xu S; Wojcik L; Wagner N; Gonsiorek W; Hipkin RW; Chou CC; Pugliese-Sivo C; Xiao Y; Tagat JR; Cox K; Priestley T; Sorota S; Huang W; Hirsch M; Reyes GR; Baroudy BM
Antimicrob Agents Chemother; 2005 Dec; 49(12):4911-9. PubMed ID: 16304152
[TBL] [Abstract][Full Text] [Related]
16. The lupane-type triterpene 30-oxo-calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti-chemotactic activities.
Barroso-González J; El Jaber-Vazdekis N; García-Expósito L; Machado JD; Zárate R; Ravelo ÁG; Estévez-Braun A; Valenzuela-Fernández A
J Biol Chem; 2009 Jun; 284(24):16609-16620. PubMed ID: 19386595
[TBL] [Abstract][Full Text] [Related]
17. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.
Klibanov OM; Williams SH; Iler CA
Curr Opin Investig Drugs; 2010 Aug; 11(8):940-50. PubMed ID: 20721836
[TBL] [Abstract][Full Text] [Related]
18. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
[TBL] [Abstract][Full Text] [Related]
19. Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.
Peng P; Chen H; Zhu Y; Wang Z; Li J; Luo RH; Wang J; Chen L; Yang LM; Jiang H; Xie X; Wu B; Zheng YT; Liu H
J Med Chem; 2018 Nov; 61(21):9621-9636. PubMed ID: 30234300
[TBL] [Abstract][Full Text] [Related]
20. Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.
Xue CB; Wang A; Han Q; Zhang Y; Cao G; Feng H; Huang T; Zheng C; Xia M; Zhang K; Kong L; Glenn J; Anand R; Meloni D; Robinson DJ; Shao L; Storace L; Li M; Hughes RO; Devraj R; Morton PA; Rogier DJ; Covington M; Scherle P; Diamond S; Emm T; Yeleswaram S; Contel N; Vaddi K; Newton R; Hollis G; Metcalf B
ACS Med Chem Lett; 2011 Dec; 2(12):913-8. PubMed ID: 24900280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
